Opinion|Videos|May 2, 2024
Unmet Needs and Clinical Data with Hepatic Artery Infusion in Intrahepatic Cholangiocarcinoma
Drs Connell and Merkow discuss the current treatment landscape in intrahepatic cholangiocarcinoma and review recent clinical data in that space.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
The FDA has issued a CRL to LNTH-2501 for the localization of SSTR-positive NETs.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
China’s NMPA has satri-cel for pretreated, CLDN18.2-positive, HER2-negative advanced gastric/GEJ adenocarcinoma.
Advertisement
Advertisement
Trending on OncLive
1
Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC
2
The OncFive: Top Oncology Articles for the Week of 6/28
3
FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies
4
Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera
5